Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 424  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14: Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
09/04/2014 > 175 patent applications in 103 patent subcategories.

20140248209 - Anti-tumoral compound and relative production process: An anti-tumoral compound for the localized treatment of neoplastic pathologies of malignant kind that cannot be surgically removed or with a high risk of local recurrence, includes: a bicomponent injectable biologic glue; an antineoplastic substance; and an epinephrine-based solution. The compound may be used as an independent therapeutic treatment, as... Agent: Seventeen Srl

20140248210 - Multimodal silica-based nanoparticles: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1... Agent: Sloan-kettering Institute For Cancer Research

20140248211 - Method of treating cancer: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides... Agent: Intensity Therapeutics, Inc.

20140248212 - Non-immunogenic positron emission tomography reporter gene systems: Embodiments of the invention include a PET/SPECT reporter gene system that uses enhanced non-immunogenic versions of a human mitochondrial thymidine kinase 2 expressed in cytoplasm to preferentially trap novel PET/SPECT radiolabeled L and D-enantiomer analogs of the natural substrate thymidine. Such highly sensitive, non-immunogenic reporter genes function in combination with... Agent: The Regents Of The University Of California

20140248213 - Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties: The present invention provides for heptamethine cyanine dyes that possess both nuclear and near-infrared imaging capabilities. These dyes can be used for imaging, targeting and detecting tumors in patients.... Agent: University Of Virginia Patent Foundation

20140248214 - High-concentration aqueous dispersions of graphene using nonionic, biocompatible copolymers: Methods of using a surface active block copolymer to disperse graphene in an aqueous medium, such dispersions which can be subsequently separated and processed for a range of end-use applications, including biomedical applications.... Agent:

20140248216 - Drug delivery by carbon nanotube arrays: The invention generally relates to carbon nanotube based drug delivery methods, devices, and compositions. More particularly, the invention relates to controlled drug delivery using anchored carbon nanotube arrays.... Agent: California Institute Of Technology

20140248217 - Methods of identifying xenohormetic phenotypes and agents: Methods of identifying a xenohormetic induced phenotype in an organism are provided. Also provided are methods if using organisms having a known xenohormetically induced phenotype in a number of different applications, such as the identification of xenohormetic agents and the generation of chemical entities and foodstuffs under specific conditions of... Agent: Palo Alto Investors

20140248215 - Uses and compositions for treatment of psoriatic arthritis: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for... Agent:

20140248218 - Ros-sensitive fluorescent probes: Herein are provided, inter alia, compositions including boronic esters, which in the presence of H2O2, provide for the detection of ROS compounds such as endogenous H2O2 and methods of using the compositions to detect ROS compounds.... Agent: The Regents Of The University Of California

20140248220 - Foamable suspension gel: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.... Agent: Stiefel Research Australia Pty Ltd

20140248219 - Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses: The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further... Agent: Foamix Ltd.

20140248221 - Compositions for oral use and methods for treating the oral mucosa, lips, and perioral regions: Compositions containing polymetal complexes useful in treating disorders of the oral mucosa, lips, and perioral regions are described.... Agent: Jr Chem, LLC

20140248222 - Dental varnish compositions: Disclosed herein are substantially transparent and colorless dental varnishes having improved fluoride release, transparency and color once coated.... Agent: Dentsply International Inc.

20140248224 - Aqueous photo-protective personal care composition: The invention relates to a high SPF/UVAPF sunscreen composition. It is an object of the present invention to provide an SPF of at least 10 and a UVAPF of at least 2. This is achieved by inclusion of a select emollient in a sunscreen containing composition comprising a cosmetically acceptable... Agent: Conopco, Inc., D/b/a Unilever

20140248223 - Film compositions for delivery of actives: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain at least... Agent: Monosol Rx, LLC

20140248225 - Nail-hardening cosmetic composition, use of aldehydes to harden and strengthen nails, and method for applying same: A cosmetic composition for nails containing a concentration less than or equal to 1 wt % of at least one monoaldehyde of the formula (I): R—CHO, where R is C5-C12 linear alkyl radical or a C5-C12 alkenyl with an unconjugated double bond to the —CHO aldehyde group, as nail hardening... Agent: Fiabila

20140248226 - Method for treating vascular inflammation, improving skin beauty and improving male sexual function using ginseng berry: The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject.... Agent: Amorepacific Corporation

20140248227 - Deodorizing compositions: Cosmetic compositions for reducing body odor include a) at least one alkoxybenzene compound having the structural formula (I), having the residues R1 and R2, wherein R1 is selected from a C1 to C8 alkyl group and R2 is selected from a C1 to C8 alkyl group and a C2 to... Agent: Henkel Ag & Co. Kgaa

20140248230 - Hair care treatment agent: Hair treatment agents include at least one quaternary ammonium compound according to formula (I), in which n denotes an integer from 10 to 24 and X− denotes an anion, at least one quaternary ammonium compound according to formula (II) in which m denotes an integer from 10 to 24 and... Agent: Henkel Ag & Co. Kgaa

20140248229 - Nourishing hair treatment composition: Hair treatment compositions, including at least one quaternary imidazoline derivative having at least two long fat residues of the formula (I) set forth herein, in which the R1 and R2 residues are each independently a saturated or unsaturated, linear or branched hydrocarbyl residue having a chain length of 18 to... Agent:

20140248228 - Hair treatment composition with cationic care substance and uv filter: Hair treatment agents combining improved care effects, in particular improved combability, softness and shine of the hair, with a viscosity stability over wide temperature ranges include—relative to their weight—0.1 to 20 wt. % of at least one UV filter and 0.1 to 30 wt. % of at least one compound... Agent: Henkel Ag & Co. Kgaa

20140248231 - Biocompatible hydrogel treatments for retinal detachment: Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the... Agent: Medicus Biosciences LLC

20140248232 - Biodegradable, non-thrombogenic elastomeric polyurethanes: A method of forming an implantable article includes providing a biodegradable polymer including anti-thrombogenic groups along the length of the biodegradable polymer, biodegradable groups in the backbone of the biodegradable polymer and a plurality of functional groups adapted to react with reactive functional groups on a surface of the implantable... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20140248233 - Biocompatible composite materials: An injectable composite material comprising a fibrous material comprised of a fir biocompatible low melting point polyester dispersed in a host medium comprised of second biocompatible low melting point polyester.... Agent: The University Of Manchester

20140248234 - Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases: The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function... Agent: Generon Shanghai Corporation Ltd.

20140248235 - Methods of use for il-22 promoting rejuvenation of thymic and bone marrow function: The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer... Agent: Memorial Sloan-kettering Cancer Center

20140248236 - Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.... Agent:

20140248238 - Polypeptide constructs and uses thereof: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression... Agent: Teva Pharmaceuticals Australia Pty Ltd

20140248237 - Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties... Agent:

20140248239 - Triazine compounds as pi3 kinase and mtor inhibitors: and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this... Agent: Wyeth LLC

20140248241 - 3'-deoxy nucleosides for the treatment of hcv: d

20140248240 - Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt): The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: Formula (I)... Agent:

20140248242 - Thiophosphate nucleosides for the treatment of hcv: e

20140248246 - Edible web comprising microorganisms: The present invention relates to edible webs comprising microorganisms, such as probiotics. In particular, the present invention relates to an edible web having microorganisms, such as bacteria, probiotic bacteria, bacteriophages or viruses printed thereon, e.g. by the use of inkjet printing. In addition the invention relates to methods of producing... Agent:

20140248247 - Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease: The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion of healthy bone... Agent:

20140248243 - Virus-like particles for treatment of viral infections: The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA... Agent: Ben-gurion University Of The Negev Research And Development Authority

20140248245 - Diagnostic method for connective tissue and its application: The present invention relates to medicine and is used to evaluate conditions and to detect connective tissue pathology (and/or organ) by clonal analysis. The present invention relates to aesthetic medicine and is used for correction of aging skin changes. The method includes: cultivation of substrate-dependent cell colonies of analyzed tissue... Agent: Obshhestvo S Ogranichennoi Otvetstvennost'yu "vitacel"

20140248244 - Mesenchymal stem cells expressing tnf-alpha receptors: Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.... Agent:

20140248248 - Human progenitor t-cells: Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem... Agent: Sunnybrook Health Sciences Centre

20140248249 - Method for stabilization and delivery of therapeutic molecules: A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and one or more of a natural molecule or fragment thereof in at least one carrier to a patient in need of treatment, wherein the natural molecule is non-acetylated, non-Esterified, and non-fatty acid attached.... Agent:

20140248250 - Agent exhibiting bactericidal action with respect to vegetative and spore cells bacillus anthracis, anthrax preventing and treating method: The drug has a bactericidal effect on vegetative and spore cells of Bacillus anthracis and comprises a bacteriolytic complex produced by Lysobacter sp. XL 1. The bacteriolytic complex produced by is in a method of anthrax prevention and treatment.... Agent: Uchrezhdenie Rossiiskoi Akademii Nauk Institut Biokhimi I

20140248251 - Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance: The invention concerns methods for protecting a subject in need from a deleterious effect of gluten ingestion. The invention specifically concerns the treatment of celiac disease and gluten intolerance. The invention further provides pharmaceutical compositions for protecting a subject in need from a deleterious effect of gluten ingestion, and, in... Agent:

20140248252 - New salt and medical use: The present invention is directed to 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof for the treatment of a disease associated with elevated blood uric acid levels, such as hyperuricemia or gout. The invention is also directed to the tosylate salt of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide.... Agent: Pfizer Limited

20140248253 - Compositions and methods for the treatment of cns injuries: The present invention is directed to a method of improving functional recovery following a central nervous system contusion injury. The method includes administering a therapeutically effective amount of glycosaminoglycan degrading enzyme. The glycosaminoglycan degrading enzyme may be dermatan sulfate or chondroitin sulfate degrading enzymes. The central nervous system contusion injury... Agent: Acorda Therapeutics, Inc.

20140248256 - Dimeric bacteriophage lysins: The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or... Agent:

20140248255 - Novel asparaginase and treating diseases associated with asparagine dependence: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity... Agent: Children's Hospital Los Angeles

20140248254 - The use of ache as nuclease: This invention provides the use of AChE as nuclease. The use of AChE in regulating the stability of nucleic acid and cell apoptosis, as well as a series of agents based on the use, including the agents for promoting or inhibiting cell apoptosis, the agents for inhibiting tumors, and the... Agent: Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences

20140248257 - Combination therapy for ischemia: The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment invoices administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g. by administration of tPA). Administration a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion... Agent:

20140248259 - Compositions and methods for modulating hemostasis: Factor X/Xa variants and methods of use thereof are disclosed.... Agent: The Children's Hospital Of Philadelphia

20140248258 - Methods for improving gut health: The present invention provides methods for improving gut health. In particular, the invention provides methods for improving gut health by improving the digestibility of dietary proteins, decreasing the flow of protein to the lower gastrointestinal tract, and/or decreasing the levels of Clostridium bacteria the upper intestinal tract of a subject.... Agent: Novus International, Inc.

20140248260 - Use of toll-like receptor agonist for treating cancer: The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.... Agent: Cleveland Biolabs, Inc.

20140248261 - Antibody against mutant alpha-actinin-4: An antibody against mutant α-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of α-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.... Agent: Trans Genic Inc.

20140248267 - Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in... Agent: Immunogen Inc.

20140248266 - Anti-cd40 antibody mutants: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the... Agent: Kyowa Hakko Kirin Co., Ltd.

20140248263 - Bisphenol compounds and methods for their use: Compounds having a structure of Formula I: wherein G, a, Q, L2, R1, R2, R3, R4, R5 and R6 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.... Agent: British Columbia Cancer Agency Branch

20140248262 - Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.... Agent: Genentech, Inc.

20140248268 - Rab7 gtpase inhibitors and related methods of treatment: This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or... Agent:

20140248264 - Small molecule trail gene induction by normal and tumor cells as an anticancer therapy: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain... Agent: The Penn State Research Foundation

20140248265 - Therapeutic antibodies binding il 12rbeta1: The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of... Agent: Novartis Ag

20140248269 - Medicinal agent for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor gc-a and gc-b agonists: Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind... Agent: Osaka University

20140248270 - Method for topical treatment of tar-responsive dermatological disorders: A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the... Agent:

20140248271 - Novel human genes relating to respiratory diseases and obesity: This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.... Agent: Oscient Pharmaceuticals Corporation

20140248272 - Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same: The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in Treponema spp. isolated from digital dermatitis in cattle. The present invention further relates to antibodies raised against said proteins or fragments thereof, and... Agent:

20140248273 - Vaccine based on staphylococcal superantigen-like 3 protein (ssl3): The present invention relates to the field of vaccinology, especially of vaccines against Staphylococcus aureus, for both human and veterinary application. In particular the invention relates to a Staphylococcal superantigen-like 3 (SSL3) protein or its homolog, an immunogenic fragment of either protein, for use in a vaccine against S. aureus.... Agent:

20140248274 - Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies: The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilisate as well as the use of a sugar or... Agent: Roche Diagnostics Gmbh

20140248275 - Multiple-variable dose regimen for treating tnfalpha-related disorders: Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor... Agent: Abbvie Biotechnology Ltd.

20140248276 - Multiple-variable dose regimen for treating tnfalpha-related disorders: Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor... Agent: Abbvie Biotechnology Ltd.

20140248277 - Multiple-variable dose regimen for treating tnfalpha-related disorders: Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor... Agent:

20140248278 - Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer: This invention provides methods for preventing, reducing, delaying or inhibiting the proliferation and/or growth and/or metastasis of lung cancers and prostate cancer that express or overexpress CD22 by contacting the lung cancer cell or prostate cancer cell with an antigen binding molecule that binds to CD22 expressed on the surface... Agent: The Regents Of The University Of California

20140248279 - Use of il-23 and il-17 antiagonists to treat autoimmune ocular inflammatory disease: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.... Agent: The Government Of The United States Of America As Represented By The Secretary Of The Department Of

20140248280 - Anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers: Provided are methods and compositions for clinical treatment of advanced gynecological cancers using anti-ErbB3 antibodies combined with paclitaxel.... Agent: Merrimack Pharmaceuticals, Inc.

20140248281 - Erythropoietic role of resident macrophages in hematopoietic organs: Methods of determining the erythroid prognosis of an anemia, methods of treating a blood disorder in a subject comprising an anemia, and methods of treating a blood disorder in a subject comprising an expanded erythron are all provided.... Agent: Albert Einstein College Of Medicine Of Yeshiva University

20140248284 - Methods for the detection and the treatment of cardiac remodeling: The present invention relates to methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure. The present invention also relates to methods and pharmaceutical compositions for the prevention and the treatment of cardiac remodeling.... Agent:

20140248283 - Monoclonal antibodies against her2 antigens, and uses therefor: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that... Agent: Alper Biotech, LLC

20140248282 - Novel anti-ddr1 antibody having anti-tumor activity: As a result of producing anti-DDR1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human DDR1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains.... Agent: Chugai Seiyaku Kabushiki Kaisha

20140248286 - Anti-hemagglutinin antibodies and methods of use: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.... Agent: Genentech, Inc.

20140248285 - Method for protecting parvovirus antigen: An improved method for the detection of parvovirus B19 in a sample is provided, the improvement consisting of detecting a parvovirus B19 non-structural protein in said sample.... Agent: Novartis Ag

20140248288 - Biodegradable metal alloys: The invention relates to biodegradable, metal alloy-containing compositions, methods for their preparation and applications for their use. The compositions include magnesium and other components, such as yttrium, calcium, silver, cerium, and zirconium; or zinc, silver, cerium, and zirconium; or aluminum, zinc, calcium, manganese, silver, yttrium; or strontium, calcium, zinc. The... Agent: University Of Pittsburgh-of The Commonwealth System Of Higher Education

20140248287 - Fc receptor binding proteins: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.... Agent: Dyax Corp.

20140248289 - Methods and compositions for the treatment of respiratory conditions via nkg2d inhibition: Methods and compositions for the treatment of respiratory conditions are provided. Aspects of the subject methods include administering to the subject a composition comprising an inhibitor of NKG2D-mediated activation of leukocytes. Also provided are compositions suitable for use in the subject methods, as well as pharmaceutical preparations thereof.... Agent: The Regents Of The University Of California

20140248292 - Compositions and methods for treating cancer: The present invention relates to compositions and methods for treating cancer. In particular, the present invention relates to EpCAM-targeted immunotoxins and uses thereof in treating peritoneal cancers expressing EpCAM (e.g., colorectal, ovarian, and pancreatic cancer).... Agent: Oslo Universitetssykehus Hf

20140248290 - Inhibition of cancer metastasis: P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors... Agent: The Board Of Trustees Of The University Of Arkansas

20140248291 - Modulation of cellular migration: Methods, kits, and compositions are provided for addressing cancer through the interaction of bradykinin (BK) and the bradykinin-2-receptor (B2R). This interaction controls cellular invasion, as has been unexpectedly observed in glioma cells, A composition is provided for the treatment of cancer by disrupting this interaction using an inhibitor or BK... Agent: The Uab Research Foundation

20140248293 - Novel risk biomarkers for lung cancer: Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of N-methylpurine DNA glycosylase (MPG), or apurinic/apyrimidinic endonuclease 1 (APE1), or both, or MPG and 8-oxoguanine DNA glycosylase (OGG1), or MPG and APE1... Agent: Yeda Research And Development Co., Ltd

20140248294 - Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases: Provided are novel methods and compositions for the diagnosis, prognosis and treatment of gynecological tumors, in particular uterine leiomyoma (UL). Furthermore, novel methods and compositions for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of pituitary and prostate... Agent: University Of Bremen

20140248295 - Glycan-modified anti-cd4 antibodies for hiv prevention and therapy: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.... Agent: The Rockefeller University

20140248296 - Sustained drug delivery system: A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be... Agent:

20140248298 - Bioresorable polymer matrices and methods of making and using the same: Bioactive agents are delivered to a body site in need of the same by providing a first aliquot portion of a reaction mixture which includes an aldehydic polymer solution, and a second aliquot portion of a reaction which includes a cross-linking hydrazide and a bioactive agent. The first and second... Agent: Royer Biomedical, Inc.

20140248297 - Predictors of response to immunotherapy: The invention is directed to a method to predict individuals who are likely to respond to immunotherapy by detecting enhanced levels of antibodies in the plasma or serum wherein the antibodies are characteristic of the response or non-response of pretested populations of subjects.... Agent: Novarx Corporation

20140248299 - Vinyl-phenyl derivatives for inflammation and immune-related uses: e

20140248300 - Peptide vaccines for cancers expressing tumor-associated antigens: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148,... Agent: Oncotherapy Science, Inc.

20140248301 - Method of inducing the production of protective anti-hiv-1 antibodies: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable... Agent:

20140248302 - Recombinant proteins and their therapeutic uses: A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen,... Agent: Bioven 3 Limited

20140248303 - Synthetic streptococcus pneumoniae vaccine: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R21 or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a... Agent: St. Jude Children's Research Hospital

20140248304 - Non-hemolytic llo fusion proteins and methods of utilizing same: The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The... Agent: The Trustees Of The University Of Pennsylvania

20140248305 - Adenoviral vectors comprising partial deletions of e3: This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3... Agent: The Wistar Institute

20140248307 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.... Agent:

20140248308 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.... Agent:

20140248306 - Lentiviral gene transfer vectors and their medicinal applications: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors... Agent: Centre National De La Recherche Scientifique

20140248309 - Dna promoters and anthrax vaccines: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.... Agent: Government Of The U.s.a, As Represented By The Secretary, Dept. Of Health & Human S

20140248310 - Cationic metal oxides for use as vaccine adjuvants: Adjuvant and immunological vaccine compositions comprising modified, cationic metal oxides are disclosed, including methods of making modified, cationic metal oxides and methods of using the modified metal oxides in vaccine formulations and regimens.... Agent:

20140248311 - N-terminal deleted gp120 immunogens: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.... Agent: Children's Medical Center Corporation

20140248312 - Influenza vaccines including combinations of particulate adjuvants and immunopotentiators: Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen;... Agent: Novartis Vaccines And Diagnostics Srl

20140248313 - Combination adjuvant formulation: Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance... Agent: The University Of British Columbia

20140248314 - Pre-fusion rsv f antigens: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.... Agent: Novartis Ag

20140248316 - Hybrid cells for treating cancer patients: The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation.... Agent: Orbis Health Solutions LLC

20140248315 - Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine... Agent: Colorado State University Research Foundation

20140248318 - Natural antioxidant anti-influenza composition: The invention relates to a composition from the extract of Myrciaria dubia and Echinacea purpurea, which has a synergistic effect. The composition of the invention has potentiated antioxidant and anti-flu properties, as well as a high immuno-stimulating capacity.... Agent: Pharmabrand S.a.

20140248317 - Trehalose compound, method for producing same, and pharmaceutical product containing the compound: A trehalose compound having high immunopotentiating activity and low toxicity is represented by formula (1). (In the formula, X and X′ each represents a phenyl, a naphthyl, R1—CHR1— (wherein R1 and R2 each represents a C7-C21 alkyl group or the like) or the like; and n and n′ each independently... Agent: Glytech, Inc.

20140248320 - Adjuvanted influenza b virus vaccines for pediatric priming: The influenza B strain is epidemiologically relevant in the pediatric population. Immunogenic priming of children with influenza B vaccine adjuvanted with an oil-in-water emulsion primes an immune response to a booster vaccine comprising influenza B virus antigen from a different strain or lineage, irrespective of whether the booster comprises an... Agent:

20140248319 - Multicomponent and biocompatible nanocomposite materials, methods of synthesizing same and applications of same: One aspect of the present invention relates to a method of synthesizing a multicomponent and biocompatible nanocomposite material, which includes: synthesizing a gold/hydroxyapatite (Au/HA) catalyst; distributing the Au/HA catalyst into a thin film; and heating the thin film in a reactor with a carbon source gas to perform radio frequency... Agent: Board Of Trustees Of The University Of Arkansas

20140248322 - Dental compositions containing silica microbeads: A dental treatment system for the relief of dental hypersensitivity and related disorders, including a dentition delivery formulation and a plurality of generally spherical vitreous microspheres generally homogeneously dispersed in the dentition delivery formulation, wherein each respective microsphere has a coating containing calcium and phosphate and wherein each respective microsphere... Agent:

20140248321 - Powdery emulsifying composition of alkyl polyglycosides, use thereof for preparing cosmetic emulsions, and method for preparing same: A powdery composition C1 contains for 100% of the mass: 5 to 70 mass % and more particularly 10 to 50 mass % of at least one compound of formula (I): R—O-(G)x—H, wherein R is a linear saturated aliphatic radical including 12 to 22 carbon atoms, G is the remainder... Agent: Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic

20140248323 - Powdery emulsifying composition of alkyl polyglycosides, use thereof for preparing cosmetic emulsions, and method for preparing same: A powdery composition C1 contains for 100% of the mass: 5 to 70 mass % and more particularly 10 to 50 mass % of at least one compound of formula (I): R—O-(G)x-H, wherein R is a linear saturated aliphatic radical including 12 to 22 carbon atoms, G is the remainder... Agent: Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic

20140248325 - Cell-free tissue replacement for tissue engineering: The present invention is a natural, cell-free tissue replacement that does not require difficult or extensive preparation made by washing tissue replacement in a solution including one or more sulfobetaines and an anionic surface-active detergent and washing the tissue replacement in serial solutions of the buffered salt to remove excess... Agent: Board Of Regents, The University Of Texas System

20140248326 - Encapsulated kidney tissue: Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising:... Agent: Advanced Technologies And Regenerative Medicine LLC

20140248327 - Interventional medical device and manufacturing method thereof: An interventional medical device and manufacturing method thereof. The interventional medical device comprises: a stent body (1); a surface of the stent body (1) being provided with a drug releasing structure (3), and drug in the drug releasing structure (3) being drug for suppressing proliferation of adventitial fibroblasts and a... Agent: Shanghai Microport Medical (group) Co., Ltd.

20140248324 - Novel multiphasic biomaterials and method of manufacturing same: The novel biomaterial fillers containing cross-linked sodium alginate and the method for manufacturing same are used in the medical field and are intended for filling tissue lesions having a layered structure of varying compositions, such as cartilage, skin or the epithelium. These novel biomaterials have the special feature of being... Agent: Universite De Lorraine

20140248328 - Methods of treating amniotic membranes using supercritical fluids and compositions and apparatuses prepared therefrom: A method of sterilizing compositions prepared from amniotic membrane tissues may include harvesting placental tissue, separation of amniotic membrane tissue, and treatment of the amniotic membrane tissue with a supercritical fluid such as carbon dioxide. Treatment with supercritical fluid may subject the amniotic membrane tissue to conditions sufficient to sterilize... Agent:

20140248329 - Therapeutic implant: Surgical implants of the present disclosed include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent... Agent: Covidien Lp

20140248330 - Device for transdermal administration of drugs including acrylic polymers: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or... Agent: Noven Pharmaceuticals, Inc.

20140248331 - Polyhydroxyalkanoate medical textiles and fibers: Absorbable polyester fibers, braids, and surgical meshes with prolonged strength retention have been developed. These devices are preferably derived from biocompatible copolymers or homopolymers of 4-hydroxybutyrate. These devices provide a wider range of in vivo strength retention properties than are currently available, and could offer additional benefits such as anti-adhesion... Agent:

20140248332 - Composition comprising an onion extract and liposomes: The present invention relates to a composition comprising a first onion extract (A), and liposomes, wherein at least a portion of the onion extract is encapsulated in the liposomes. Furthermore the present invention relates to a method for preparing a composition comprising a first onion extract (A), and liposomes, wherein... Agent: Merz Pharma Gmbh & Co. Kgaa

20140248333 - Compositions and methods for inhibiting proteases: In particular, in alternative embodiments, the invention provides pharmaceutical compounds and formulations comprising a family of epoxyketone compounds, which include racemic mixtures or racemates, isomers, stereoisomers, diastereoisomers, derivatives and analogs, and methods for making and using them. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered to... Agent: The Regents Of The University Of California

20140248338 - Compositions and methods for silencing aldehyde dehydrogenase: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or... Agent: Protiva Biotherapeutics, Inc.

20140248335 - Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof: The present invention relates, in part, to a composition comprising a multicationic drug and an organic multianion. In some embodiments, the multicationic drug is enclosed within a carrier. In some embodiments, the carrier is a liposome. In some embodiments, the multicationic drug and organic multianion are enclosed within a carrier,... Agent: Insmed Incorporated

20140248337 - Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or... Agent: Lipoxen Technologies Limited

20140248339 - Multi-component nanochains: A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain... Agent: Case Western Reserve University

20140248334 - Peptides that target dorsal root ganglion neurons: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular... Agent: Baylor College Of Medicine

20140248336 - Sirna useful in the treatment of flavivirus infection: Pharmaceutical compositions that comprise an siRNA molecule used in the treatment of diseases caused by flavivirus infection and methods of their use are disclosed. The pharmaceutical compositions treat diseases caused by yellow fever virus, West Nile virus, and dengue virus and include a single pharmaceutical composition active against all four... Agent: Oregon Health & Science University

20140248340 - Coated controlled release active agent carriers: The present invention relates to carriers for the controlled release of active agents, comprising a core, comprising surface reacted natural or synthetic calcium carbonate, and at least one active agent, wherein said at least one active agent is associated with said natural or synthetic surface-reacted calcium carbonate, and wherein said... Agent:

20140248341 - Alcohol resistant enteric pharmaceutical compositions: Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.... Agent: Alkermes Pharma Ireland Limited

20140248343 - Abuse resistant forms of extended release morphine, method of use and method of making: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and... Agent: Inspirion Delivery Technologies, LLC

20140248344 - Abuse resistant forms of extended release morphine, method of use and method of making: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and... Agent: Lnspirion Delivery Technologies, LLC

20140248342 - Fe(iii) 2,4-dioxo-1-carbonyl complexes for treatment and prophylaxis of iron deficiency symptoms and iron deficiency anaemias: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use in the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.... Agent: Vifor (international) Ag

20140248345 - Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin: This invention relates to a bilayer pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and atorvastatin, or a pharmaceutically acceptable salt thereof, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.... Agent:

20140248346 - Misuse preventative, controlled release formulation: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be... Agent: Paladin Labs (barbados) Inc.

20140248347 - Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide: The present invention relates to pharmaceutical compositions containing axitinib, which is known as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide or 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, or crystalline forms thereof, that protect axitinib from degradation, including photodegradation, as well as the therapeutic use of such compositions. The present invention also relates to novel photodegradants of axitinib.... Agent:

20140248349 - Process for the preparation of a solid, orally administrable pharmaceutical composition: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.... Agent: Bayer Intellectual Property Gmbh

20140248348 - Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore,... Agent: People's Liberation Army Of China

20140248350 - Delayed release film coatings containing calcium silicate and substrates coated therewith: The present invention includes pH dependent, dry film coating compositions containing calcium silicate for use on orally-ingestible substrates such as tablets and the like. The film coating compositions can be applied as an aqueous suspension either directly to a substrate or after the substrate has been coated with a subcoat.... Agent: Bpsi Holdings, LLC.

20140248351 - Pharmaceutical composition comprising fesoterodine: The present invention relates to a granulate and a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and stabilizer, in particular to a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and sucrose, polyethylene glycol, cyclodextrin, and combinations thereof and to a process for... Agent: Lek Pharmaceuticals D.d.

20140248352 - Chewable enteric coated aspirin tablets: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener.... Agent: Mcneil-ppc, Inc.

20140248353 - Dosage form for insertion into the mouth: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding... Agent: Nal Pharmaceuticals Ltd.

20140248355 - 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.... Agent: H. Lundbeck A/s

20140248356 - 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.... Agent: H. Lundbeck A/s

20140248354 - Controlled release vaccines and methods for treating brucella diseases and disorders: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates... Agent: The Texas A&m University System

20140248361 - Herbal extract composition and a process thereof: A composition is provided that includes extracts of green tea and rosemary extract optionally along with adjuvant and/or excipient. In addition, provided is a process for the preparation of said composition. Also provided is a composition including extract of green tea, rosemary extract and synthetic antioxidant optionally along with adjuvant... Agent:

20140248360 - Nanoparticle tumour vaccines: The present invention provides a vaccine for the prophylactic or therapeutic treatment of a tumour in a mammalian subject, as well as methods of using the vaccine, including in treatment of tumours and in generating a CTL response. The vaccine comprises a plurality of nanoparticles and a pharmaceutically acceptable carrier,... Agent:

20140248359 - Novel formulation of diclofenac: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way... Agent: Iceutica Pty Ltd.

20140248357 - Respiratory disease treatment: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight... Agent: Pulmagen Therapeutics (inflammation) Limited

20140248362 - Sustained-release preparation: Provided is a sustained-release preparation containing pioglitazone or a salt thereof as an active ingredient and showing superior sustainability. A sustained-release preparation containing pioglitazone or a salt thereof, which shows a dissolution ratio of pioglitazone of average 25-58% at the 2-hour time point, and average 60-100% at the 4-hour time... Agent:

20140248358 - Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.... Agent: Bind Therapeutics, Inc.

20140248364 - Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation: The compositions and methods of the disclosure particularly target the divalent metal transporter expressed on olfactory nerve terminals to transport divalent cation-coated or cation-containing nanoparticles to all regions of brain. It has been found that such divalent cation-containing nanoparticles, including those nanoparticles comprising manganese have affinity for the metal transport... Agent:

20140248363 - Nanoparticulate phosphate adsorbent on the basis of maghemite or maghemite/magnetite, production and uses thereof: The present invention relates to a phosphate adsorbent on the basis of maghemite or maghemite/magnetite comprising (i) an iron oxide core comprising a crystal structure of inverse spinel iron oxide, (ii) a coating selected from monomeric carbohydrates, in particular monosaccharides or disaccharides, alditols, or mixtures thereof, and/or (iii) a pharmaceutical... Agent:

20140248365 - Nanoparticle peptide compositions: The present invention relates to teriparatide peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of disorders, e.g., of bone density. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the... Agent:

20140248366 - Animal feed composition: The present invention relates to a feed composition for an animal comprising tea tree oil, wherein the tea tree oil is present in an amount sufficient to reduce bacterial infection in the animal upon ingestion of the feed composition, and to methods for preparing such a composition.... Agent:

20140248367 - Spray-dried pharmaceutical compositions comprising active agent nanoparticles: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 μm, and wherein up to 10%... Agent: Besins Healthcare Luxembourg Sarl

20140248368 - Powdery emulsifying composition of alkyl polyglycosides, use thereof for preparing cosmetic emulsions, and method for preparing same: A powdery composition C1 contains for 100% of the mass: 5 to 70 mass % and more particularly 10 to 50 mass % of at least one compound of formula (I): R—O-(G)x-H, wherein R is a linear saturated aliphatic radical including 12 to 22 carbon atoms, G is the remainder... Agent: Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic

20140248369 - Eye health composition and method using plant derived seed extract rich in essential fatty acids derived from perilla seed and carotenoids: A dietary supplement composition is formulated in a therapeutically effective amount to treat the eye of an individual. The composition includes a perilla seed oil extract, astaxanthin, and at least one carotenoid selected from the group consisting of lutein, trans-zeaxanthin and meso-zeaxanthin.... Agent: U.s. Nutraceuticals, LLC D/b/a Valensa International

20140248370 - Enhancement composition: An enhancement composition includes a combination of natural ingredients that form a synergy to enhance the health, appearance, smell, and psyche of a surface, such as skin. Unnatural or processed ingredients are not included that can cause irritation and more detrimental effects to the skin. The enhancement composition has no... Agent:

20140248371 - Spalax fibroblast-derived anti-cancer agents: A conditioned cell culture medium of cells derived from Spalax or naked mole rat (Heterocephalus glaber) and methods for preparing it are provided. Pharmaceutical compositions comprising the conditioned cell culture medium and its use in the treatment of cancer as well as methods for identifying anti-cancer agents are also provided.... Agent: Carmel-haifa University Economic Corp. Ltd.

20140248372 - Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone,... Agent: Emory University

20140248373 - Enhanced performance hydrogen peroxide formulations comprising proteins and surfactants: Disclosed herein are compositions comprising: an oxidizing agent; a surfactant; and a protein component. Also disclosed are methods of cleaning a surface, the method comprising applying an aqueous solution to the surface, the solution comprising the above compositions.... Agent: Advanced Biocatalytics Corporation

20140248374 - Compositions and multi-step methods of using the same for the treatment of jellyfish stings: Embodiments of the invention relate to a composition containing zinc and copper and methods of using the same in treatment of exposure to a pore-forming toxin (PFT) in a subject or membrane perturbant (MP).... Agent: University Of Hawaii

20140248375 - Combination therapy for treating proliferative diseases: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.... Agent: Bionomics Limited

20140248376 - Compositions for treatment of skin and ear infections: The present invention relates to a composition for the treatment of skin and ear infections in humans and animals such as dogs, cats and horses. In particular, the present invention relates to a topical composition comprising acetic acid, an antibacterial and/or an anti-fungal, and preferably also an anti-inflammatory. More specifically,... Agent: Dechra Veterinary Products, LLC

20140248377 - Multiple emulsion: The invention relates to a multiple emulsion for the application of at least one pharmaceutical or cosmetic active ingredient which has an external water phase W1, an oil phase O dispersed in the external water phase W1 and an internal water phase W2 dispersed in the oil phase O, where,... Agent: Sterna Biologicals Gmbh & Co. Kg Biomedizinisches Forschungszentrum

20140248378 - Pyrimidinone compounds and their use: The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Takeda Pharmaceutical Company Limited

20140248379 - Process for producing an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material, and cannabis extracts: The invention relates to a method for producing an extract from cannabis plant matter, containing tetrahydrocannabinol, cannabidiol and optionally the carboxylic acids thereof. According to said method, the dried pint matter is ground and subjected to a CO2 extraction and the primary extract obtained is separated. The invention method permits... Agent: Delta-9-pharma Gmbh

20140248381 - Composition for inhibiting vascular aging comprising syringaresinol: The present invention discloses a composition for inhibiting vascular aging comprising a compound of Chemical formula 1, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.... Agent:

20140248380 - Method for treating vascular inflammation, improving skin beauty and improving male sexual function using ginseng berry: The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject.... Agent: Amorepacific Corporation

20140248382 - Curcuminoid-based compound/stevioside-containing complex for the prevention and treatment of an influenza virus infection: The present invention relates to a complex comprising a compound of formula (I), or a plant extract comprising the compound or a fraction thereof; and stevioside, or a plant extract comprising the stevioside or a fraction thereof, and relates to a pharmaceutical composition for preventing or treating an influenza virus... Agent: Korea Research Institute Of Bioscience And Biotechnology

20140248383 - Sleep quality improving agent: An object is to provide a sleep quality improving agent that can sufficiently exert the effect of improving the quality of sleep and ensures safety for the body. A sleep quality improving agent containing, as an effective ingredient, a plant of the Fraxinus genus such as Fraxinus excelsior L., an... Agent: Lion Corporation

  
08/28/2014 > 222 patent applications in 129 patent subcategories.

20140241983 - Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with... Agent: The Wistar Institute Of Anatomy And Biology

20140241984 - Alpha-synuclein antibodies and uses thereof: The invention describes antibodies having a high affinity for aggregated forms of α-synuclein and a low affinity for monomeric forms of α-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.... Agent: United Arab Emirates University

20140241985 - Chelated psma inhibitors: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.... Agent: Cancer Targeted Technology LLC

20140241986 - Formulations of fluorinated stilbene suitable for pet imaging: The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations... Agent: Piramal Imaging Sa

20140241987 - Alpha-synuclein antibodies and uses thereof: The invention describes antibodies having a high affinity for aggregated forms of α-synuclein and a low affinity for monomeric forms of α-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.... Agent: United Arab Emirates University

20140241991 - Chimeric non-human animal carrying human hepatocyte: A chimeric non-human animal having an in vivo human hepatocyte population, wherein the effects of non-human animal cells on drug metabolism are suppressed or deleted is provided. A method for producing a chimeric non-human animal that lacks a drug-metabolizing system or has a suppressed drug-metabolizing system and is provided with... Agent: National University Corporation Tottori University

20140241988 - Methods and compositions for treating atrial fibrillation: The present invention relates to compositions and methods for the prevention and treatment of atrial fibrillation. In particular, the present invention provides therapeutic agents for the treatment and prevention of persistent and permanent atrial fibrillation and prevention of progression of atrial fibrillation to permanent atrial fibrillation.... Agent: The Regents Of The University Of Michigan

20140241990 - Methods of using adenosine a1 receptor activation for treating depression: Disclosed herein are methods for treating depression and depressive-like symptoms by administering a therapeutically effective amount of an adenosine 1 receptor agonist. Also disclosed herein are methods for identifying adenosine receptor agonists and the use of identified adenosine receptor agonists for treating diseases, disorders or conditions characterized by pathological sleep... Agent: Tufts University

20140241989 - Novel imaging agents, process for the preparation thereof and pharmaceutical compositions containing same: Compounds of formula (I) in which: >R is a linear or branched (C1-C6) alkyl, >L is a spacer group, >A is a diagnostic agent, and >m is equal to 1 or 2.... Agent: Les Laboratoires Servier

20140241996 - Therapeutic nanoparticles and methods of use thereof: Provided herein are therapeutic nanoparticles having a diameter of between 10 nm to 30 nm, and containing a polymer coating, and a nucleic acid containing a sequence complementary to a sequence within a micro-RNA identified as having a role in cancer cell metastasis or anti-apoptotic activity in a cancer cell... Agent: The General Hospital Corporation

20140241993 - Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer: A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.... Agent: Fred Hutchinson Cancer Research Center

20140241992 - Nanostructure, applied device and preparation method thereof: A nanostructure is described. The nanostructure includes a nanoparticle, a shell encompassing the nanoparticle, and a gap having a width ranging from 1.0 nm to 6.0 nm and located between the nanoparticle and the shell to enable the nanostructure to generate a fluorescence.... Agent: National Cheng Kung University

20140241994 - Method and system for calculating a quantification indicator for quantifying a dermal reaction on the skin of a living being: This method is designed for calculating a quantification indicator for quantifying a dermal reaction on a skin having several chromophores. The method includes illumination of a zone to be characterized on the skin, the skin reaction being included in the zone to be characterized; and measurement of the spectrum of... Agent: Commissariat A L'energie Atomique Et Aux Energies Alternatives

20140241995 - Micropatch for assessing chemical contact allergy: The micropatch of the present invention provides a reliable and effective system of elicitation necessary for the diagnostic identification of allergy cases whilst substantially reducing the chances of sensitising subjects, the present invention employs a micropatch.... Agent: Hds Ltd.

20140241997 - Wound treatment: Use of a moulding composition comprising a polymer and a setting agent for wound debridement, wherein said use comprises adding water to said moulding composition to form a moulding fluid, applying said moulding fluid to a surface of a wound, allowing said moulding fluid to set in contact with said... Agent:

20140241998 - Body cavity foams: The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable... Agent: Foamix Ltd.

20140241999 - Peptide linkers for effective multivalent peptide binding: Short single chain peptides having affinity for a target surface often lack the binding durability required for certain commercial applications. One way to improve durability is to promote multivalent binding by linking together binding sequences using peptide linkers. However, the resulting single chain binding peptides often suffer from linker entropy.... Agent: E. I. Du Pont De Nemours And Company

20140242000 - Composition, comprising hydrofluoric acid, for inhibiting dental erosion: The present invention relates to a composition, for inhibiting dental erosion, and the use thereof. The composition comprises an aqueous solution of hydrofluoric acid, in which the concentration of hydrofluoric acid is 0.05%-2.00% and the pH is between 2.5 and 4.5.... Agent: Zpearpoint As

20140242001 - Tooth film formulations: The invention provides novel dental film-forming compositions, comprising i. an acrylate/octylacrylamide copolymer, ii. one or more alkyl cellulose ethers, and iii. a solvent, and optionally further comprising whitening materials and/or active agents, together with method for using the same.... Agent: Colgate-palmolive Company

20140242002 - Mouthwash composition: wherein X═H, Na, K, NH4, ½Ca, or ½Mg, and Y═Cl, Br, or I. The modified polyglutamic acid in the mouthwash composition is 0.1-5 wt %. The mouthwash composition in the present invention can eliminate bad breath, and also has antibacterial properties, so it can suppress the formation of dental plaque... Agent: Far Eastern New Century Corporation

20140242003 - Oral care compositions: The present invention relates to oral compositions, comprising select polyethylene oxide-polypropylene oxide block copolymer surfactants. Methods for using the compositions are also disclosed.... Agent: Mcneil-ppc, Inc.

20140242004 - Oral care compositions: The present invention relates to oral compositions, comprising select polyethylene oxide-polypropylene oxide block copolymer surfactants. Methods for using the compositions are also disclosed.... Agent: Mcneil-ppc, Inc.

20140242005 - Method for oral care: The present invention relates to method for treating or preventing tooth decay, gum disease or sensitive teeth and to compositions, devices and kits for use in this method. The method comprises the application of an oral care composition to the gum and teeth of an individual using an applicator. In... Agent: Multi Oral Bv

20140242009 - Bioactive compositions from theacea plants and processes for their production and use: The present invention relates to isolated bioactive compositions containing bioactive fractions derived from Theacea plants. The present invention also relates to bioactive topical formulations containing the bioactive compositions. The present invention further relates to methods of using the bioactive compositions of the present invention, including, for example, methods for inhibiting... Agent: Akzo Nobel Surface Chemistry LLC

20140242010 - Method and compositions for treating skin: A method for increasing and/or synchronizing per1 gene expression in skin cells having decreased, irregular, or asynchronous per1 gene expression comprising treating the skin cells with an effective amount of cichoric acid, and the resulting compositions.... Agent:

20140242007 - Topical preparation containing ngf for inducing skin pigmentation and for the treatment of cutaneous dyschromias and vitiligo: m

20140242006 - Topical sunscreen compositions: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, a solid, organic UV-filter dissolved therein; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than 13.9. The composition has... Agent: Johnson & Johnson Consumer Companies, Inc.

20140242008 - Topical sunscreen compositions: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, a solid, organic UV-filter dissolved therein; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than 45, where the composition... Agent: Johnson & Johnson Consumer Companies, Inc.

20140242011 - Composition having a reduced exotherm in actinic curing of urethane (meth)acrylate oligomers on fingernails: A nail coating composition having a reduced exotherm during actinic curing of the coating on a nail. The composition may include a curable resin, a monomer, a photoinitiator, a chemical filter capable of absorbing ultraviolet (UV) light and reducing exotherm, and an additive.... Agent: O P I Products, Inc.

20140242013 - Herbal composition for skin-whitening and anti-skin-aging, method of preparation and the use thereof: This invention provides a Chinese medicinal formula comprising Atractylodis Macrocephalae Rhizoma, Glycyrrhizae Radix et Rhizoma, Angelicae sinensis Radix, Paeoniae Radix Alba and Poria for skin care. It further relates to a method for preparing bioactive fraction of this formula and to the applications of the bioactive fraction in skin-whitening and... Agent: Hong Kong Baptist University

20140242012 - Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate: i

20140242014 - Compositions containing an acrylic film former, a tackifier and an ester: The invention relates to a composition, especially a cosmetic composition, comprising at least one ester of polyol(s) and of fatty diacid dimer or an ester thereof, at least one acrylic film forming agent and at least one tackifier, as well as to methods of using such compositions.... Agent: L'oreal

20140242015 - Antiperspirant/deodorant compositions: Antiperspirant/deodorant compositions have lower, or even zero amounts of aluminium and/or zirconium antiperspirant actives. A polymer having one or more anhydride and/or diacid moieties, such as succinic (maleic) anhydride and/or diacid. The antiperspirant/deodorant compositions comprise a polymer with a non-zero acid value and a cationic species, which may be a... Agent: Isp Investments Inc.

20140242016 - Non-aqueous solid stabilized emulsions: wherein the oil phase (a) is dispersed as discontinuous droplets in the polar phase (b); the silica particle dispersant (c) is absorbed on the surface of the oil phase (a); and the silica particle dispersant (c) is partially wetted by the polar phase (b).... Agent: Stiefel Laboratories, Inc.

20140242017 - Cosmetic compositions, method for preparing a cosmetic composition, cosmetic use of the composition and cosmetic method for straightening and/or shaping keratinous materials: The present invention relates to a new cosmetic product for treating keratinous materials, particularly hair, to the method for preparing the cosmetic product, and to a cosmetic method for the care of keratinous material using these compositions.... Agent:

20140242018 - Liquid non-ionic salt-free skin and hair treatment composition that contains n-methyl lauroyl glucamide: Compositions and methods for of their use in treating human or other mammalian skin and hair. Non-ionic, salt-free non-solidifying formulations of Lauroyl N methyl-C10, C12, C14, C16 alkanoyl-N-methyl-glucamide and alkyl glycosides are disclosed that impart beneficial barrier properties to skin and hair.... Agent: Formula Xo, Inc.

20140242019 - Composition for preventing hair loss and growing hair comprising hydroxydihydrobovolide: There is provided a new use of a hydroxydihydrobovolide compound having effects on preventing hair loss and growing hairs. Since the hydroxydihydrobovolide compound has effects on increasing survival rates of human hair follicle dermal papilla cells and hair outer root sheath cells and also growing a length of hairs, the... Agent: Pukyong National University Industry-university Cooperation Foundation

20140242020 - Ginger extract for the protection of stem cells: e

20140242021 - Waterless animal bath: Generally, compositions which can be applied to hair, fur or skin of an animal and are useful for reducing, removing or eliminating undesirable materials or odors or parasites (“extraneous matter”) from the hair, fur or skin of the animal. Specifically, compositions which can be applied to hair, fur or skin... Agent: Sirius Products, Inc.

20140242022 - Compositions for the treatement of dry eye: The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.... Agent:

20140242023 - Topical compositions and methods of using the same: The present invention relates generally to topical compositions and methods of using the same.... Agent: Novan, Inc.

20140242024 - Hydrogel implants with varying degrees of crosslinking: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with... Agent: Covidien Lp

20140242026 - Compounds, compositions, and methods for preventing metastasis of cancer cells: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.... Agent:

20140242025 - Multimeric il-15 soluble fusion molecules and methods of making and using same: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).... Agent: Altor Bioscience Corporation

20140242028 - Antiviral compounds: e

20140242027 - Substituted pyridine and pyrimidine derivatives and their use in treating viral infections: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and... Agent: Merck Sharp & Dohne Corp.

20140242029 - Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using... Agent: Boehringer Ingelheim International Gmbh

20140242030 - Novel anti-hcv agent: Provided is a novel anti-HCV agent including as an active ingredient a peroxide derivative represented by the general formula (I). In the general formula (I), C represents an alicyclic hydrocarbon ring group which may be substituted, n represents an integer of from 1 to 6, and R represents a hydrogen... Agent: National University Corporation Okayama University

20140242031 - Adeno-associated virus virions with variant capsid and methods of use thereof: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.... Agent: The Regents Of The University Of California

20140242033 - Gene therapy vectors and cytosine deaminases: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.... Agent: Tocagen Inc.

20140242032 - Modified bacteriophage including an alpha/beta small acid-soluble spore protein (sasp) gene: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an α/β small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage... Agent: Phico Therapeutics Ltd.

20140242048 - Methods for controlling pests: Involved is a method for controlling the pest Sesamia inferens, comprising the step of contacting Sesamia inferens with Cry1B protein. Sesamia inferens is controlled by the Cry1B protein having pesticidal activity against Sesamia inferens, which is produced in the plants. Compared with the agricultural control, chemical control and biology control... Agent: Beijing Dabeinong Technology Group Co., Ltd., Biotech Center

20140242049 - Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy: A transformed T-cell for T-cell therapy, and a composition including the same for anticancer immunotherapy. More particularly, the transformed T-cell is characterized by the transfection of a gene for coding a chimera protein. The T-cell, to which the gene for coding the chimera protein is transected, may improve the therapeutic... Agent: National Cancer Center

20140242047 - Transgenic therapeutic stem cells and methods for their use and manufacture: The invention relates to transgenic stem cells for therapeutic use. Stem cells according to the invention comprise at least one therapeutic trans gene that is expressed when transplanted to a subject. Methods of use and manufacturing the transgenic stem cells of the invention are also contemplated, including the use of... Agent:

20140242034 - Probiotics for use in relieving symptoms associated with gastrointestinal disorders: The present invention provides probiotic compositions suitable for relieving symptoms associated with gastrointestinal disorders. In particular, the present invention provides compositions and methods to relieve symptoms associated with functional bowel disorders, irritable bowel syndrome, functional diarrhea, functional bloating, and other symptoms.... Agent:

20140242035 - Methods and systems for treating cell proliferation disorders: e

20140242050 - Nutritional composition comprising probiotics and improving sleep patterns: This invention relates to the use of a probiotic bacterial strain in the manufacture of a medicament or therapeutic nutritional composition for improving the maturation of sleep patterns in infants, young children or young animals and/or for reducing sleep disturbances and/or improving sleep patterns in humans or animals at any... Agent: Nestec S.a.

20140242051 - Probiotic, lactic acid-producing bacteria and uses thereof: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant... Agent: Ganeden Biotech, Incorporated

20140242052 - Treatment and/or prophylaxis of storage diseases of harvested material: The present invention relates to the treatment and/or prophylaxis of storage diseases of harvested material.... Agent: Sourcon-padena Gmbh & Co.kg.

20140242036 - Process for potentiating the production of lingzhi mushroom (ganoderma lucidum) substances and antifungal activity thereof: The instant invention refers to a novel process for potentiating the production of substances with antifungal activity obtained from Ganoderma lucidum, using a technological device for the differential, qualitative and quantitative expression of proteins and other bioactive molecules, selected from the group consisting of polysaccharides, triterpenoids, fatty acids and ganoderic... Agent:

20140242037 - Apc-mediated tolerance induction for therapy of multiple sclerosis: The invention relates to transgene expression constructs—particularly self inactivating lentiviral vectors—comprising a dendritic cell specific promoter controlling the expression of autoantigen proteins, namely myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein, for use in the therapy of multiple sclerosis.... Agent:

20140242039 - Adherent cells from adipose or placenta tissues and use thereof in therapy: A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A... Agent: Pluristem Ltd.

20140242044 - Devices and methods for treating defects in the tissue of a living being: An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery. Additionally, the implant may include, or have blended in, an additive, such as an osteoinductive... Agent: Kensey Nash Bvf Technology LLC

20140242046 - Inhibition and enhancement of reprogramming by chromatin modifying enzymes: Methods and compositions are provided for the production of stem cells and induced pluripotent stem cells, and for uses thereof.... Agent: Childern's Medical Center Corporation

20140242038 - Method for generating beta cells: The invention is directed to methods for generating pancreatic progenitor cells, insulin producing cells or endoderm cells using embryonic stem cells and induced pluripotent stem cells. The present invention also relates to an isolated population comprising pancreatic progenitor cells or a insulin-producing cells, compositions and their use in the treatment... Agent: The Trustees Of Columbia University In The City Of New York

20140242045 - Methods and compositions for delivering interleukin-1 receptor antagonist: Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in... Agent: Biomet Biologics, LLC

20140242042 - Methods for preventing and treating hemorrhoids: The invention is directed to methods for treating hemorrhoids. The invention is also directed to methods for preventing hemorrhoids. The invention is further directed to reducing inflammation associated with hemorrhoids. The invention is further directed to methods for preventing hemorrhoids and/or treating hemorrhoids and/or reducing inflammation associated with hemorrhoids by... Agent: Stemnion, Inc.

20140242040 - Methods for preventing and/or treating nasal polyps and rhinosinusitis: The invention is directed to methods for preventing and/or treating nasal polyps. The invention is further directed to methods for preventing and/or treating rhinosinusitus. The invention is further directed to reducing inflammation of the paranasal sinuses. The invention is further directed to methods for preventing and/or treating nasal polyps and/or... Agent: Stemnion, Inc.

20140242041 - Methods for preventing or treating necrotizing enterocolitis: The invention is directed to methods for preventing and/or treating necrotizing enterocolitis. The invention is further directed to reducing inflammation of the intestinal mucosa associated with necrotizing enterocolitis. The invention is further directed to methods for preventing and/or treating necrotizing enterocolitis and/or inflammation of the intestinal mucosa associated with necrotizing... Agent: Stemnion, Inc.

20140242043 - Methods for preventing or treating optic neuritis: The invention is directed to methods for preventing and/or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. The invention is further directed to methods for preventing and/or treating optic neuritis and/or inflammation associated with the development of optic neuritis by... Agent: Stemnion, Inc.

20140242053 - Method for using directing cells for specific stem/progenitor cell activation and differentiation: A method is provided, including obtaining a population of antigen-presenting cells, enriching a population of stem/progenitor cells within a larger population of cells, activating the population of antigen-presenting cells and, following the activating, inducing at least one process selected from the group consisting of: differentiation, expansion, activation, secretion of a... Agent: Biogencell, Ltd

20140242054 - Methods and compositions for treating respiratory conditions using platelet enriched plasma: Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in... Agent: Vetgel Technologies

20140242055 - Compositions containing non-polar compounds: Provided herein are compositions and methods for preparing foods and beverages that contain additives, such as nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and... Agent:

20140242057 - Conjugated factor viii molecules: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.... Agent: Novo Nordisk A/s

20140242056 - Preparation of stabilized catalase enzymes using polyvinyl alcohol: There is provided a method of producing a stabilized catalase enzyme. In the method, a substrate is thoroughly mixed with phosphate borate and catalase, rinsed with water and the solids dried. The dried solid may be mixed with polyvinyl alcohol and dried for further stabilization. The stabilized powder may be... Agent: Kimberly-clark Worldwide, Inc.

20140242058 - St6gal i mediated modulation of hematopoiesis: Provided are methods for reducing haematocytes in an individual. The method involve administering to an individual a composition that contains recombinant a2,6-sialyltransferase (ST6Gal I). The method is suitable for prophylaxis and therapy of a condition that is positively correlated with undesirable hematopoiesis. Such conditions include autoimmune diseases, transplantation rejection, blood... Agent: Health Research, Inc.

20140242059 - Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.... Agent: Green Cross Corporation

20140242060 - Compositions of engineered human arginases and methods for treating cancer: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human... Agent: Aerase, Inc.

20140242061 - Compositions and methods for treating gaucher disease: Methods and compositions for treating Gaucher disease are described.... Agent: Shire Human Genetic Therapies, Inc.

20140242062 - Modified proteases that inhibit complement activation: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be... Agent: Catalyst Biosciences, Inc.

20140242065 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.... Agent:

20140242064 - Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets: A system for delivering a therapeutic agent to a nasopharyngeal mucosa target comprises a foam generating mechanism, a gas, a therapeutic agent in liquid form that inhibits mucus production, and a delivery device. Actuation of the foam generating mechanism entraps gaseous bubbles from the gas in the liquid thereby forming... Agent: The Foundry, LLC

20140242063 - Pharmaceutical compositions: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective... Agent: Valeant Laboratories International Bermuda

20140242066 - Formulation and treatment for acne: The present invention relates to composition comprising Lactobacillus rye ferment, dialkylisosorbide and phospholipid. Preferably, the composition further comprises ethoxylated sorbitan fatty acid ester. The composition has been shown to be effective against infections of closed comedones. The invention further relates to a method of preparing the composition, to a roll-on... Agent:

20140242067 - Treatment of central nervous system disorders by intranasal administration of immunoglobulin g: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal... Agent: Baxter International Inc.

20140242068 - Jaml specific binding agents, antibodies, and uses related thereto: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.... Agent: Emory University

20140242072 - Anti-icam-1 antibodies to treat multiple-myeloma related disorders: The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods... Agent: Bioinvent International Ab

20140242070 - Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer: Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates Fzd2. The antibody may specifically bind... Agent: President And Fellows Of Harvard College

20140242069 - Krt19 stabilizing her2 and use thereof: Provided is a method of decreasing the stability of HER2 (human epidermal growth factor receptor 2) in a cell or individual comprising administering an effective amount of an expression or activity inhibitor of KRT19 (cytokeratin 19) to the cell or individual.... Agent:

20140242071 - M-csf specific monoclonal antibody and uses thereof: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.... Agent: Novartis Vaccines And Diagnostics Inc.

20140242073 - Cartilage/bone destruction suppressor: An object of the present invention is to provide a cartilage/bone destruction suppressor which can suppress the destruction of cartilage or bone seen in rheumatoid arthritis, osteoarthritis, bone metastasis of malignant tumor, or the like. The present invention relates to a cartilage or bone destruction suppressor comprising an antibody against... Agent: Kagoshima University

20140242074 - Materials and methods for modulating activity of bone marrow derived cells: The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating 5 conditions amenable to treatment by recruitment of bone marrow-derived cells, such as... Agent: University Of Florida Research Foundation, Inc.

20140242075 - Antibody variants and uses thereof: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.... Agent: Genmab B.v.

20140242079 - Bispecific t cell activating antigen binding molecules: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for... Agent: Roche Glycart Ag

20140242080 - Bispecific t cell activating antigen binding molecules: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for... Agent: Roche Glycart Ag

20140242081 - Dosing regimens for treatment of cea-expressing cancers: The present disclosure provides compositions and methods for treating CEA-expressing cancers. Methods for dosing a patient with an antibody that binds to CEA and human CD3 are also provided.... Agent: Medimmune, LLC

20140242077 - Methods and compositions for modulating an immune response: Provided are multispecific binding proteins and methods for using these multispecific binding proteins to modulate the activation state of immune cells, such as T-cells (e.g., cytotoxic T-cells). Also provided are methods of modulating an immune response (e.g., cell killing by cytotoxic T-cells) in a subject (e.g., a human subject). Also... Agent: Abbvie, Inc.

20140242078 - Methods and monitoring of treatment with a wnt pathway inhibitor: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.... Agent: Oncomed Pharmaceuticals, Inc.

20140242076 - Multispecific mutated antibody fab fragments: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.... Agent: Azienda Ospedaliera Para Giovanni Xxiii

20140242084 - Angiopoietin-like 4 and its use in modulating cell leakiness: Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated... Agent: Nanyang Technological University

20140242083 - Anti-mcsp antibodies: The invention provides anti-MCSP antibodies and methods of using the same.... Agent: Roche Glycart Ag

20140242082 - Combination therapy for the treatment of ocular neovascular disorders: The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention... Agent: Ophthotech Corporation

20140242085 - Methods and composition for testing, preventing, and treating aspergillus fumigatus infection: As a result of the analysis by an SST-REX method so as to identify a target molecule for treating and testing an Aspergillus fumigatus infection, a YMAF1 protein has been found out, which is mainly localized in the cell wall of Aspergillus fumigatus. Moreover, it has been found out that... Agent: National Institute Of Infectious Diseases

20140242086 - Polynucleotides encoding signal peptide-containing molecules: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.... Agent: Incyte Corporation

20140242088 - Hsp90 inhibitor combinations: A pharmaceutical combination comprising an Hsp90 inhibitor and an mTOR inhibitor, and methods of using the combination to treat or prevent proliferative disorders.... Agent: Novartis Ag

20140242087 - Modulation of the vps10p-domain receptor family for the treatment of mental and behavioural disorders: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried... Agent: H. Lundbeck A/s

20140242089 - Glycoproteins having lipid mobilising properties and therapeutic applications thereof: A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α2-glycoprotein, or of a fragment thereof having an apparent molecular mass Mr greater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material... Agent: Aston University

20140242091 - Method for treating pathologies associated with hypoxia using mif inhibitors: Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for reating a subject having, or at risk from, a CNS disorder associated with... Agent: The Feinstein Institute For Medical Research

20140242090 - Methods for the treatment of il-1beta related conditions: Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies or binding fragment thereof).... Agent: Xoma Technology Ltd.

20140242092 - Vhz for diagnosis and treatment of cancer: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility... Agent: Agency For Science, Technology And Research (a*star)

20140242093 - Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject: In one aspect, the present invention relates to methods for increasing, decreasing or maintaining the innate immune response in a mammalian subject comprising modulating the expression of DUX4-fl, or modulating the expression of beta-defensin 3 (DEFB103). In another aspect, the present invention relates to methods for increasing, decreasing or maintaining... Agent: Fred Hutchinson Cancer Research Center

20140242094 - Methods related to tim 3, a th1-specific cell surface molecule, for activating antigen presenting cells: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed... Agent: The Brigham And Women's Hospital, Inc.

20140242095 - Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers: The invention relates to modulating the SIRPα—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRPα antibodies and antibody fragments, preferably used for treating hematological cancer.... Agent: University Health Network

20140242096 - Compositions and methods related to graft versus host disease and treatments thereof: Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection,... Agent: The Regents Of The University Of Colorado, A Body Corporate

20140242097 - Methods: s a biguanidine moiety or carbamoylguanidine, and the other moiety may be biguanidine or carbamoylguanidine or amine; and cationic moieties G4 and G5 do not contain single guanidine groups. The entry-promoting agent may comprise homogeneous or heterogeneous mixture of one or more of agents arising from formulae 1 a and... Agent: The Royal Veterinary College

20140242099 - Compounds for inflammation and immune-related uses: The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent:

20140242098 - Drug dispensing and dosing method and device: Flexible film or strip dosing device and method for various therapeutic applications are disclosed. The device includes at least one film or strip and a packaging container for the film or strip. The film or strip normally include a polymer base with or without a therapeutic agent admixed with the... Agent: Monmouth University

20140242100 - Methods and compositions for the generation and use of conformation-specific antibodies: The present invention features methods and compositions for the generation of conformation-specific antibodies.... Agent: Beth Israel Deaconess Medical Center, Inc.

20140242101 - Pd-l1 based immunotherapy: The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions comprising PD-L1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious... Agent: Herlev Hospital

20140242103 - Composition: The present invention provides a modified influenza virus wherein the RNA of the haemagglutinin gene has been modified such that the haemagglutinin signal sequence is not expressed and the virus produces a haemagglutinin protein that lacks a functional signal sequence. The invention further provides composition comprising the modified virus and... Agent: Isis Innovation, Ltd.

20140242102 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... Agent: Medimmune, LLC

20140242104 - Self-assembling peptide nanoparticles as vaccines against infection with norovirus: Self-assembling peptide nanoparticles (SAPN) incorporating T-cell epitopes and displaying the P domain of the norovirus protein VP1 are described. The nanoparticles of the invention consist of aggregates of a continuous peptide chain comprising two coiled coil oligomerization domains connected by a linker segment wherein one or both oligomerization domains incorporate... Agent: Alpha-o Peptides Ag

20140242106 - Staphylococcus aureus proteins and nucleic acids: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.... Agent: Novartis Ag

20140242105 - Vaccines for chlamydia: The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus Chlamydia. In particular, the present invention relates to isolated B- and T-cell epitopes derived from the major outer membrane protein of Chlamydia psittaci which can be used against an infection with... Agent: Universiteit Gent

20140242107 - Direct protein delivery with engineered microvesicles: The present invention relates to direct protein delivery with engineered micro vesicles.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)

20140242108 - Conjugated tlr7 and/or tlr8 and tlr2 polycationic agonists: A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II:... Agent: Cayla

20140242109 - Method for cultivating alga and method for producing alginic acid-containing composition: The objective of the present invention is to provide a method for cultivating an alga having ability to produce alginic acid industrially and effectively and a method for producing an alginic acid-containing composition industrially advantageously. The method for cultivating an alga according to the present invention is characterized in comprising... Agent: Kaneka Corporation

20140242110 - Dose, localization, and formulation of botulinum toxins in skin and muscle: Formulations of and dosing protocols for the administration of botulinum toxin that maximize efficacy and specificity while minimizing the likelihood of overdosing and undesirable side effects of treatment. The formulations include positively charged carriers, such as cationic peptides, which otherwise have no inherent botulinum-toxin-like activity. The dosing regimen is based... Agent:

20140242111 - Engineered bacteria for oral delivery of glucoregulatory proteins: Disclosed is an oral delivery system that overcomes major barriers encountered in the gastrointestinal tract, particularly rapid proteolytic degradation and low intestinal permeability. Provided is a method for oral delivery of an engineered microorganism to a mammal where the microorganism produces a macromolecule having a desired bioavailability outcome.... Agent: The Trustees Of The University Of Pennsylvania

20140242112 - Novel vaccine: The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) 7 agonist in an orally (e.g. sublingually) administered composition.... Agent: Glaxosmithkline Biologicals S.a.

20140242113 - Liquid vaccine preparations: This document provides methods and materials involved in making and using liquid vaccine preparations for oral administration. For example, methods and materials for making and using liquid vaccine preparations for oral administration that include a lyophilized or dried vaccine component (e.g., a lyophilized pathogenic agent such as a lyophilized rotavirus... Agent:

20140242114 - Cdna construct of salmonidae alphavirus: The invention concerns recombinant DNA's comprising cDNA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNAs are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines.... Agent:

20140242115 - Inactivating pathogens with oxidizing agents for vaccine production: The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions... Agent: Oregon Health And Science University

20140242116 - Spray dried compositions and methods of use: Provided herein are insoluble particles that include polypeptides. The polypeptides may have immunogenicity that is greater than the immunogenicity of the same polypeptides when they are not present in the particle. The polypeptides may be soluble before incorporation into the particles and insoluble after incorporation into the particles. The particles... Agent: Life-science Innovations, LLC

20140242117 - Vaccine composition capable of inducing memory antibody response from single point immunization: The present investigation relates to entrapment of carbohydrate antigen such as Vi polysaccharide of Salmonella typhi in poly (DL) lactide (PDLLA) and polylactide-co-glycolide (PLGA) polymer particles. The formulated product not only elicits primary antibody titers from single dose application but also evokes memory antibody titer against the T independent antigen.... Agent: National Institute Of Immunology

20140242118 - Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy: In one aspect, the present invention provides a method for treating cancer comprising tumor cell vaccination in combination with hematopoietic and immune cell transplantation. In some embodiments, the method involves autologous tumor cell vaccination prior to autologous hematopoietic and immune cell transplantation. In another aspect, the present invention provides a... Agent:

20140242119 - Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies: wherein X, R1, R2, R3, R4, R5, n, R1a, R2a, R3a, R4a, R5a, R6a, R7a, Xa and na are defined herein; or the N-oxide derivatives thereof or prodrugs thereof, or a pharmaceutically acceptable salt, solvate or hydrate thereof. The invention further provides combinations of a compound of Formula V or... Agent: Novartis Ag

20140242121 - Novel imidazole quinoline-based immune system modulators: The present invention relates to a compound of Formula I: or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.... Agent: Janus Biotherapeutics, Inc.

20140242120 - Substituted aromatic compounds for inflammation and immune-related uses: e

20140242124 - Agonists of guanylate cyclase and their uses: This invention provides a method of colonic cleansing.... Agent:

20140242122 - Crystalline glycopyrrolate tosylate: Salts of glycopyrrolate, including solid forms thereof are herein disclosed. Methods of making glycopyrrolate salts and methods of treating hyperhidrosis with salts of glycopyrrolate are disclosed.... Agent: Dermira, Inc.

20140242126 - Dendritic macroporous hydrogels prepared by crystal templating: The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with... Agent:

20140242125 - Muscle tissue regeneration using muscle fiber fragments: The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and... Agent: Wake Forest University Health Sciences

20140242123 - Saccharide-peptide hydrogels: The disclosure provides for saccharide-peptide based hydrogels, the functionalization of the saccharide-peptide based hydrogels with one or more biological agents, and the encapsulation of one or more biological materials and/or pharmaceutical agents in the hydrogels. The disclosure further provides for the use of the saccharide-peptide based hydrogels in treating a... Agent:

20140242128 - Composite powder and method for producing same: An object of the present invention is to provide a composite powder that is stable even if it is present in water for a long time. A composite powder, comprising: an inorganic powder; a first coating layer containing a water-repellent organic compound on the surface of the inorganic powder; and... Agent: Sakai Chemical Industry Co., Ltd.

20140242131 - Composition containing a cellulose derived capsule with a sunscreen: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be... Agent: Colabs International Corporation

20140242132 - Composition containing a cellulose derived capsule with a sunscreen: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be... Agent: Colabs International Corporation

20140242127 - Compositions with thermally-regulating material: Cosmetic compositions for topical application to the skin comprising at least one phase change material (PCM) in combination with a cosmetically compatible carrier, and methods for maintaining the skin of a wearer of a cosmetic product at a comfortable temperature, are provided.... Agent: Elc Management LLC

20140242134 - Cosmetic composition: The invention relates to cosmetic compositions comprising a water-in-oil emulsion comprising hydrophobically modified particles, amino functionalized silicone and water; the cosmetic composition further comprising a viscosity modifying agent and optical light modifying agent. The invention further relates to a method of modifying the optical appearance of skin comprising the step... Agent: Conopco, Inc. D/b/a Unilever

20140242133 - Encapsulated low viscosity hydrophobic liquid actives: The present invention provides personal care compositions, as well as methods for protecting low viscosity hydrophobic liquid actives.... Agent:

20140242129 - Photoprotective personal care composition: A photoprotective personal care composition. The invention to a photoprotective personal care composition. The invention more particularly relates to a sunscreen composition that not only provides high sun protection but does that with minimal or no amount of traditionally used organic sunscreens. It is thus objects of the present invention... Agent:

20140242130 - Seaweed-derived cosmetic compositions: A cosmetic composition is disclosed for applying to skin. The composition includes a liquid and dispersed in the liquid: any amount or form of fucoidan, any amount or form of beta glucan; and any amount of a marine extract. When the cosmetic composition is applied to the skin, the appearance... Agent:

20140242135 - Compositions for inhibition of insect sensing: In one aspect, the invention relates to chemical modulators of insect olfactory receptors. In particular, compounds and compositions are provided that can inhibit sensory (e.g., host targeting) functions in airborne insects such as mosquitos. Method of employing such agents, and articles incorporating the same, are also provided. This abstract is... Agent: Vanderbilt University

20140242137 - Glycolate formulation for preserving wood and like materials: Compositions and methods for use in treating, in particular, lignocellulosic substrates such as lumber, are provided; wherein said compositions comprise a preservative or biocidal species, other than boron, in the form of a glycolate. The methods may be used for the purpose of, for example, preventing the growth of pest... Agent: Matterworks One Limited

20140242136 - Spray apparatuses, uses of diatomaceous earth, and methods of controlling insect populations: There is disclosed a spray apparatus for holding contents comprising diatomaceous earth and a compressed propellant for propelling the diatomaceous earth. There is also disclosed use of diatomaceous earth to control a population of bedbugs, wherein the diatomaceous earth comprises remains of pennate diatoms. There is also disclosed a method... Agent:

20140242138 - Applications of microencapsulated essential oils: Method for the preparation of microencapsulated essential oils or a formulation thereof for various non-agricultural applications.... Agent: Botanocap Ltd.

20140242139 - Controlled drug delivery: A medical device for placement in a body of a mammal is provided. The medical device comprises (1) a polymeric matrix forming the device and defining a lumen through the device, the matrix comprising polymer macromolecules and defining spaces between the polymer macromolecules; (2) a drug contained within at least... Agent: Boston Scientific Scimed, Inc.

20140242140 - Fabrication method for stratified and layered tissue to repair osteochondral defects: Fabrication method for stratified and layered tissue to repair osteochondral defects. In a method of the present disclosure, the method comprises the step of applying a first direction magnetic field to a first quantity of a first collagen solution to align collagen within the first collagen solution in a first... Agent: Purdue Research Foundation

20140242141 - Polymeric/inorganic composite materials for use in medical devices: In one aspect, the present invention provides composite coatings for implantable or insertable medical devices. These composite coatings comprise (a) an inorganic portion and (b) a polymeric portion that comprises a poly(vinyl pyrrolidone) (PVP) block.... Agent: Boston Scientific Scimed, Inc.

20140242143 - Adipose stromal vascular fraction cell constructs: Three-dimensional tissue constructs are described, which may be created by isolating adipose-derived stromal vascular fraction (SVF) cells, plating the cells onto a polymer scaffold, and culturing the plated scaffold in a culture of DMEM with approximately 10% FBS.... Agent: University Of Louisville Research Foundation, Inc.

20140242142 - Cell secreted proteins for the treatment of myocardial infarction: The present invention relates to the use of secreted proteins from mesenchymal stem cells and other cells for the treatment of myocardial infarction. In particular, the invention provides compositions and methods based on secreted proteins from mesenchymal stem cells and the genes encoding them.... Agent: National University Of Ireland, Galway

20140242144 - Drug eluting scaffold for kidney-related disease: Methods of treating renal cancers and other kidney-related inflammatory disorders with a bioabsorbable polymer scaffold (such as a stent) are described. The treatments are provided as alternative to complete or partial surgical removal of a diseased kidney.... Agent: Abbott Cardiovascular Systems Inc.

20140242147 - Adsorbents for oral administration: The present invention aims to provide an adsorbent for oral administration comprising ACF that has high adsorption or removal performance by adsorbing or removing toxic substances in the living body greatly and rapidly. The present invention is an adsorbent for oral administration comprising activated carbon fibers for treating or preventing... Agent: Teijin Pharma Limited

20140242145 - Chitosan nanofiber for anionic protein drug delivery, method of preparing the same, and pharmaceutical preparation for transmucosal administration comprising the chitosan nanofiber: A chitosan nanofiber for delivering an anionic protein drug, a method of preparing the same, and a pharmaceutical preparation for transmucosal administration including the chitosan nanofiber are provided. The chitosan nanofiber including an anionic protein drug in a core and chitosan in a shell is prepared by coaxial electrospinning an... Agent: Knu-industry Cooperation Foundation

20140242146 - Filament based on hyaluronic acid in the form of free acid and method for obtaining it: The present invention relates to a method for preparing by wet spinning a continuous filament based on hyaluronic acid in free acid form, notably soluble in water. The preparation method according to the invention comprises the following steps: a) preparing a spinnable aqueous solution of hyaluronic acid or of a... Agent: Universite Claude Bernard Lyon I

20140242148 - Antimicrobial materials and methods: The invention provides methods and materials for decontamination of surfaces and fabrics, such as non-woven fabrics, that are contaminated with infestations of microorganisms such as bacteria. Biocidal oligomers having conjugated oligo-(aryl/heteroaryl ethynyl) structures and comprising at least one cationic group can be used to decontaminate infested surfaces in the presence... Agent: University Of Florida Research Foundation, Inc.

20140242149 - High-viscosity silicone adhesive: Provided in various embodiments are high viscosity, shear-thinning silicone compositions that can be pattern coated directly onto a substrate and silicone compositions having high-density particles suspended in an adhesive gel. The silicone compositions contain a thixotropic additive, such as a hydrogenated vegetable oil. The silicone compositions may be applied on... Agent: Dow Corning Corporation

20140242151 - Adhesive skin patch: The present invention provides an adhesive skin patch that permits excellent and prolonged percutaneous absorption of tulobuterol and that can be stably applied to the skin for a long period of time with less skin irritation. The adhesive skin patch comprises a base material and a medicated layer provided on... Agent: Sekisui Chemical Co., Ltd.

20140242150 - Therapeutic compositions and methods of treatment with capsianoside-type compounds: The present invention discloses the use of certain compounds as therapeutic agents, and in particular as analgesics and anti-inflammatory agents. Such compounds include, for example, certain diterpene monoglycosides and diterpene diglycosides. The compounds of the present invention may be synthesized or isolated from the fruit of the genus Capsicum, and... Agent: Bmb Patent Holding Corporation

20140242154 - Compounds, compositions, methods, and kits relating to telomere extension: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20140242155 - Compounds, compositions, methods, and kits relating to telomere extension: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20140242157 - Epicatechin compositions and methods: Provided herein are methods and compositions for treating a subject who has pulmonary damage or an injury caused by or who is at risk for an injury caused by an anti-vesicant agent. The compositions comprise cacao extracts that include a mixture of epicatechin and one or more epicatechin oligomers and... Agent: Cacao Bio-technologies, LLC

20140242152 - Immunogenic compositions and uses thereof: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms—a first epitope from a pathogen, in RNA-coded form; and a second epitope from the same pathogen, in polypeptide form—are effective in inducing immune response... Agent:

20140242156 - Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current: Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome... Agent: Signpath Pharma Inc.

20140242153 - Novel encochleation methods, cochleates and methods of use: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo... Agent: Rutgers, The State University Of New Jersey

20140242158 - Granular pharmaceutical composition: The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing... Agent: Astellas Pharma, Inc.

20140242160 - Calcium supplement: An oral dosage form for administration to an animal comprising a biologically utilizable form of calcium and an extended release system that maintains the calcium level in the animal's bloodstream at a substantially beneficial level for a defined period of time.... Agent: Bayer Healthcare LLC

20140242159 - Method for preparing a granulate formulation of pirfenidone and pharmaceutically acceptable excipients: A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient... Agent: Intermune, Inc.

20140242161 - Soft gelatin capsules: The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule.... Agent:

20140242162 - Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the... Agent:

20140242163 - Amantadine compositions and methods of use: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.... Agent: Adamas Pharmaceuticals, Inc.

20140242165 - Biocompatible carrier containing a bioadhesive material: A biocompatible carrier for delivery of a therapeutic substance or an active agent is disclosed. The carrier contains a bioadhesive material allowing for increased residence time of the active agent at the treatment site.... Agent: Abbott Cardiovascular Systems Inc.

20140242164 - Composition and method of obtaining oral or enteral dosage forms of phytochemicals from pomegranates: Nutraceutical compositions for improved administration of important phytochemicals from pomegranate to a human or animal. More particularly, enables oral or enteral dosage forms containing phytochemicals from pomegranate for administering on a routine basis. In at least one instance the natural contents of a pomegranate are encapsulated into a pill form... Agent: Pom Wonderful, LLC

20140242167 - Pharmaceutical compositions for glucocorticoid replacement therapy: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period... Agent: Duocort Pharma Ab

20140242166 - Sustained release matrix systems for highly soluble drugs: Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable... Agent: Penwest Pharmaceuticals Co.

20140242168 - Swellable coated tablet: The present invention provides perorally administrable drug release systems and processes for producing perorally administrable systems having a drug-containing core and a sheath which surrounds the core and comprises a swellable shell and an elastic coating which surrounds at least the shell, the sheath having at least one orifice.... Agent: Lts Lohmann Therapie-systeme Ag

20140242169 - Tapentadol compositions: The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release Tapentadol Hydrochloride and therapeutically effective amount of a second analgesic, wherein the second analgesic is gamma-aminobutyric acid (GABA) analogue. The present... Agent: Gruenenthal Gmbh

20140242170 - Corticosteroids for the treatment of joint pain: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid... Agent: Flexion Therapeutics, Inc.

20140242171 - Oil-in-water emulsion of mometasone and propylene glycol: Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, propylene glycol and water and the weight ratio between the propylene glycol and water... Agent: Galenica Ab

20140242172 - Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.... Agent: Vertex Pharmaceuticals Incorporated

20140242173 - Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents: This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. Also disclosed are compositions and methods relating to synthetic nanocarriers that... Agent: Selecta Biosciences, Inc.

20140242174 - Treating cough and tussive attacks: The invention is directed towards carcainium in the form of a salt having an anion An−, wherein An− is an anion of pharmaceutically acceptable acid for use in the treatment and/or suppression of cough, tussive attacks or tussive episodes in a patient.... Agent: Verona Pharma PLC

20140242176 - Compositions, methods, and devices for the treatment of eye stain: Embodiments provided herein relate to compositions, methods, and devices useful for treating eye stain. More particularly, compositions and devices are provided that include tylosin and a carrier suitable for ophthalmic application. Such compositions and devices can be used to treat eye stain in an animal, such as a dog or... Agent: Ader Enterprises, Inc.

20140242175 - Nano-encapsulated, controlled drug delivery, manufacturing process and system: A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated in at least one layer of a protective material having the same core drug or different core drug. A mixed dose of a nanosized drug wherein at least... Agent:

20140242177 - Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly... Agent: Nova Southeastern University

20140242178 - Taste-masked formulations of raltegravir: Disclosed are taste-masked pharmaceutical formulations of raltegravir comprising coated API granules mixed with a screened powder excipient blend in either tablet or sachet form. The core and coated granules are produced using a Wurster process for enhanced control of particle size. Also disclosed are methods of treating HIV, e.g., in... Agent:

20140242179 - Novel coating system: The present patent application relates to a novel coating system, coated compositions with such a coating system, as well as to the use of such compositions in the production food, feed, dietary supplements and/or pharmaceutical products, as well as to food, feed, dietary supplements and/or pharmaceutical products comprising such compositions.... Agent: DsmIPAssets B.v.

20140242180 - Nanoparticles for controlling bleeding and drug delivery: A temperature stable nanoparticle is provided comprising a core, a water soluble polymer and a peptide, the water soluble polymer attached to the core at a first terminus of the water soluble polymer, the peptide attached to a second terminus of the water soluble polymer, the peptide comprising an RGD... Agent:

20140242181 - Preparation of fibrin gel for use as implant system: The present invention aims to generate a fibrin gel for cell proliferation and transport using the patient's own blood or compatible blood. The gel-preparation process consists in taking a quantity of blood from the patient, using sodium citrate as anticoagulant, separating off the citrated plasma by centrifugation, and resuspending the... Agent:

20140242182 - Formulations that stabilize proteins: In one aspect, the disclosure provides formulations that stabilize proteins, wherein the formulations comprise a buffer. In some embodiments, the buffer comprises potassium mono-hydrogen-phosphate and potassium di-hydrogen-phosphate, or the buffer comprises sodium mono-hydrogen-phosphate and sodium di-hydrogen-phosphate. In some embodiments, the protein is a therapeutic protein. In some embodiments, the therapeutic... Agent: Revo Biologics, Inc

20140242183 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.... Agent:

20140242184 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.... Agent:

20140242186 - Guided bone regeneration membrane and manufacturing method thereof: A guided bone regeneration material is disclosed. The guided bone regeneration material includes biodegradable fibers produced by an electrospinning method. The biodegradable fibers produced by the method include a silicon-releasing calcium carbonate and a biodegradable polymer. The silicon-releasing calcium carbonate is a composite of siloxane and calcium carbonate of vaterite... Agent: Orthorebirth Co. Ltd.

20140242185 - Method of enhancing health of a person: A method of enhancing health of a person includes administering stable water clusters to persons having an autoimmune disease, pain, a chronic disease, a mental disease, a genetic disease from malfunction of a normal DNA, being an athlete for improving his performance and alleviating soreness, suffering from overworking, stress and... Agent: D&y Technologies

20140242187 - Iron-fiber composition, preparation and uses thereof: Compositions comprising ferrous and/or ferric iron compounds and fiber in a complex, methods for preparing such compositions of matter, and the use thereof for treatment of adsorbing certain accessible targets in the gastrointestinal tract and in an extracorporeal system, are provided herein.... Agent:

20140242188 - Antimicrobial compositions and methods employing same: An aqueous composition with a higher-than-neutral pH includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. This composition, as well as an acidic counterpart and solid materials, can be used in a variety of applications such as wound care, oral care, medical equipment... Agent: Next Science, LLC

20140242189 - Methods of treating gastrointestinal spasms triggered by stress: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in... Agent: Liveleaf, Inc.

20140242190 - Use of deoxyelephantopin (det) and analogues thereof for treatment of melanoma: Methods for preventing and/or reducing side effects of an anti-cancer agent in a subject in need thereof are disclosed. The method comprises administering to the subject, who is under an anti-cancer agent treatment, a composition comprising a therapeutically effective amount of isolated deoxyelephantopin and/or an analogue thereof; and a pharmaceutically... Agent: Academia Sinica

20140242191 - Prevention of starch degradation in pulp, paper or board making processes: The invention relates to biocidal systems comprising zinc ions and an oxidizing or non-oxidizing biocide, their use, and methods for preventing or decreasing starch degradation in starch-containing process waters from pulp, paper or board production processes.... Agent:

20140242192 - Clusterin antisense therapy for treatment of cancer: A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering... Agent: The University Of British Columbia

20140242193 - Lithium compositions: 2:1 cocrystals of amino acids and Li+ salts crystallize from hot water to afford water stable cationic networks based upon tetrahedral lithium cations: bilayered square grids, a lithium zeolitic metal-organic material (LiZMOM) and several lithium diamondoid metal-organic materials (LiDMOMs). The compositions may be used as a pharmaceutical for the treatment... Agent: University Of South Florida

20140242194 - Use of nitrite salts in treating tissue damage: Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically... Agent: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

20140242195 - Automotive surface conditioning system: An automotive surface treatment system can include an aqueous antimicrobial composition which is formulated for use with automotive surfaces and has a volatile organic content no greater than 0.5% by weight. The aqueous antimicrobial composition includes an antimicrobial agent which is a combination of quaternary ammonium salts, a combination of... Agent: American Covers, Inc.

20140242196 - Method of treating venomous bites: The method of treating venomous bites, such as those from snakes and scorpions, involves treatment by the administration of a therapeutically effective amount of an aqueous extract of the fruit of Juniperus phoenicea, or pharmaceutically acceptable salts thereof. In order to treat the bites of venomous snakes, scorpions and the... Agent: Umm Al-qura University

20140242198 - Botanical antimicrobial compositions: Disclosed are compositions comprising antimicrobially effective low concentrations of benzyl alcohol, one or more essential oil and one or more botanical extract. The compositions of the application may be used in personal care products including wound care products or in veterinary use. In certain embodiments, compositions are provided having antimicrobial... Agent:

20140242197 - Compositions and methods for the treatment of diseases on plants: The present invention provides a method of treating root rot fungus, particularly Armillaria, in plants comprising applying an effective amount of a composition comprising one or more surfactants, one or more alcohols, and one or more high terpene containing oil.... Agent: Oro Agri Inc.

20140242199 - Pest control formulations and methods of making and using same: Compositions useful for controlling pests are disclosed. In some embodiments, the composition includes a pesticidal natural oil and a polar aromatic solvent. Methods of making and using the compositions are disclosed.... Agent:

20140242200 - Water-soluble extracts of artemisia dracunculus (tarragon) for improvement of glucose metabolism: m

20140242201 - Compositions for increasing human growth hormone levels: Embodiments of the invention generally relate to supplements for increasing human growth hormone (hGH) levels in healthy human beings.... Agent: QualityIPHoldings, Inc.

20140242202 - Composition for reducing side- and after-effects of cancer treatment: A compound for consumption by cancer patients, or others currently suffering from side effects such as those commonly associated with chemotherapy, that supplies herbal tonics with certain properties believed to ameliorate many of the side effects discussed above, and which has taste masking properties that improve the patient's tolerance of... Agent:

20140242203 - Anti-aging composition for vitalization of retinoic acid receptor that contains mixed extract of chinese matrimony vine and pine needles as effective component: The present invention relates to an anti-aging composition that contains a mixed extract of Chinese matrimony vine and pine needles as an effective component. More specifically, the present invention relates to a composition for an external application to the skin, wherein a mixed extract of Chinese matrimony vine and pine... Agent: Amorepacific Corporation

20140242204 - Pharmaceutical composition including c3g or mulberry extracts containing c3g for preventing or treating diabetic impotence: The present invention relates to the ameliorating effects of C3G (Cyanidin-3-O-β-d-glucopyranoside) on diabetic erectile dysfunction. In particular, the present invention relates to a pharmaceutical composition and food composition for preventing or treating diabetic erectile dysfunction comprising C3G. In addition, the present invention relates to a pharmaceutical composition and food composition... Agent: Catholic University Industry-academic Cooperation Foundation

  
  
Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus


######

RSS FEED for 20140904: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.78643 seconds

PATENT INFO